FDA grants priority review to Enhertu for high-risk early breast cancer
Share
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo moved a step closer to a major label expansion for their blockbuster cancer therapy, Enhertu, after the U.S. FDA fast-tracked an application to treat patients with early-stage breast cancer at high risk of recurrence.
